Why NanoPalm?

---

Biopharmaceutical industry encounters a central challenge of low research and development (R&D) success rates owing primarily to the costs associated with drug discovery and preclinical development along with clinical trialing before FDA regulatory approval for marketing. The average capitalized R&D cost of each new drug candidate ranges between US$161 million and US$4.54 billion.  In addition to the high cost, it takes 10 to 15 years for a successful drug to reach the market. The current pharmaceutical R&D efforts often go through the three phases of conventional clinical trials that mostly fail before a drug reaches the final phase. Indeed, successful drugs account for only 10% while 90% of drug candidates fail in clinical trials. The rigorous, complex and multi-stage process of pharmaceutical R&D slows down their productivity; hence, affordable and accelerated R&D are much sought after. The market potential for clinical trials is estimated to be US$53 billion and is expected to reach US$84 billion in 2030. While the CAGR of the market is registered at 5.7%, a new technology can boost this growth rate, which is currently restricted by technological limitations and high complication rates.  The NanoPalm technology offers organ's self-targeting biorobots within the human body to maximize both the drug accumulation and stability while minimizing the drug  toxicity and side effects